FDA approved IMPAX LABS' Abbreviated New Drug Application (ANDA060469) on July 13, 1971, giving the company regulatory clearance to manufacture a generic version of an un-named blockbuster drug; this approval is expected to drive incremental revenue by tapping into immediate market share demand without impacting the brand owner's volume.